Drug Trial Radar · NCT07623616
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Mar 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
ziftomenibDrug
Oral adminitration once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- CR+CRh rateTime frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Chiba Aoba Municipal Hospital
Chiba, Japan
Gifu Municipal Hospital
Gifu, Japan
Hyogo Medical University Hospital
Hyōgo, Japan
Mito Medical Center
Ibaraki, Japan
Imamura General Hospital
Kagoshima, Japan
Kanagawa Cancer Center
Kanagawa, Japan
Kyoto University Hospital
Kyoto, Japan
Tohoku University Hospital
Miyagi, Japan
Matsumoto National Hospital
Nagano, Japan
Nagasaki University Hospital
Nagasaki, Japan
Kurashiki Central Hospital
Okayama, Japan
Okayama University Hospital
Okayama, Japan
Kansai Medical University Hospital
Osaka, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Jichi Medical University Saitama Medical Center
Saitama, Japan
Dokkyo Medical University Hospital
Tochigi, Japan
Jichi Medical University Hospital
Tochigi, Japan
Keio University Hospital
Tokyo, Japan
Nippon Medical School Hospital
Tokyo, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.